Actelion's heart-lung drug meets main goal in late-stage study

June 16, 2014 5:37 AM

13
0

Mass marriage for physically challenged in New Delhi

ZURICH (Reuters) - Actelion Ltd said its experimental heart and lung drug Selexipag met its primary goal in a late-stage study, giving the Swiss biotech company a potential second big seller to replenish its product pipeline.